The coronavirus vaccine produced by Johnson & Johnson is far less effective against delta and lambda variants than the original virus, New research Posted online on Tuesday.
Troublesome, the findings are the result of experiments conducted in the laboratory with blood samples and may not reflect the performance of the vaccine in the real world. However, the conclusion adds evidence that 13 million people have been vaccinated with J. & J. The authors may need a second dose of the vaccine. Ideally, it is one of the mRNA vaccines manufactured by Pfizer BioNTech or Moderna.
New research has not yet been peer-reviewed or published in scientific journals. But that’s J. Consistent with the observation of a single dose of the AstraZeneca vaccine, which has a similar architecture to & J.Vaccine — about 33 percent effectiveness For symptomatological disorders caused by delta mutants.
“The message we wanted to convey wasn’t that people shouldn’t get J. & J. It’s a vaccine, but in the future it will be boosted by another dose of J. & J. Hopefully, or back with Pfizer or Moderna, “said Nathaniel Landau, a virologist at New York University’s Grossman School of Medicine, who led the study.
Other experts said the results were what they expected, as all vaccines appear to work better with two doses. “I’m always J. & J. The vaccine is a double dose vaccine,” said John Moore, a virologist at Weill Cornell Medicine in New York.
Dr. Moore monkey And Man Shows Greater effect With 2 doses of J. & J. Vaccine, compared to single dose. He said the new study was particularly credible as it was published by a team unrelated to any vaccine manufacturer.
However, data from a new study “does not speak of the full nature of immune protection,” J. & J spokeswoman Seema Kumar said. According to a study sponsored by the company, the vaccine “produced strong and persistent activity against the rapidly spreading delta mutant,” she said.
The delta variant is the most contagious version of the coronavirus to date. It accounts for 83 percent of infectious diseases in the United States, said Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention, at a Senate hearing on Tuesday.
Variants are also mainly Recent rise Infectious Diseases: Although still low compared to last winter, cases are increasing in all 50 states and hospitalizations are increasing in almost all states. In the two weeks ending Tuesday, the country killed an average of 268 people per day.
Delta can cause more breakthrough infections than previous forms of the virus, but more than 99% of hospitalizations and deaths occur among unvaccinated people. Domestic immunization rates are stagnant, with just under 60% of adults being completely protected from the virus.
Several studies suggest that the mRNA vaccine produced by Pfizer BioNTech and Moderna remains effective against the coronavirus, including all mutants identified so far. In one recent study, for example, vaccines provoke a persistent immune response in the body, Protect for years from coronavirus..
But J. Evidence about & J. The vaccine is restricted because it was deployed after the mRNA vaccine. Most studies on the efficacy of the coronavirus vaccine have been conducted in medical centers and hospitals that rely on samples from staff vaccinated with the mRNA vaccine.
small the study Release According to researchers belonging to J. & J. The vaccine was slightly less effective against the delta mutant than the original virus, suggesting that the antibody stimulated by the vaccine increased in strength over 8 months.
Dr. Danbarouch, a virologist at the Beth Israel Deacones Medical Center in Boston, believes that Landau’s team would have increased the efficacy of the vaccine as well if they examined the data over time. J. & J data. The strength of the vaccine against the delta mutant on day 29 is not much different from that reported in his own study, Dr. Baruch said.
“Basically, I don’t think there is a discrepancy,” he said. “The problem is kinetic issues because the immune response is not static over time. It’s not just about size.” The new study also didn’t consider other elements of immune defense, he said. He added.
Dr. Landau and his colleagues examined blood samples taken from 17 people immunized with two mRNA vaccines and 10 people immunized with one J. & J. vaccine.
J. & J. The vaccine started with less efficacy than the mRNA vaccine and showed a significant reduction in efficacy against delta and lambda variants. “A low baseline means that there is very little left to counter the Delta,” said Dr. Moore. “That’s a big concern.”
Akiko Iwasaki, an immunologist at Yale University, says that only a few vaccines are given in a single dose because a second dose is required to raise antibody levels. People inoculated with J. & J. The vaccine “relies on its primary response to maintain high levels of antibody, which is especially difficult for mutants,” she said.
A second dose boosting immunity should raise enough antibody levels to counter the mutant, she said.
Look at the second shot of the mRNA vaccine, not another J. & J.Shot, may be better: Some studies have given a single dose of AstraZeneca vaccine to Pfizer-BioNTech or Modana vaccine Kick up Include Immune response It is more effective than two doses of AstraZeneca.
The Food and Drug Administration states that “fully vaccinated Americans do not need booster shots at this time,” and authorities are unlikely to change their recommendations based on laboratory studies. But the new data should encourage the FDA to revisit its recommendations, Dr. Landau said: “I hope they read our treatise and think about it.”
J. & J.Studies suggest that vaccines may be less effective against deltas
Source link J. & J.Studies suggest that vaccines may be less effective against deltas